Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

AbundRX vs BeyondMD

AbundRX
Graded #181

Lower grade

vs+0.20000000000000284
BeyondMD
Graded #176

Higher grade

The verdict

BeyondMD takes it — 66.8/100 to 66.6/100, but only just.

BeyondMD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Telehealth clinic offering competitively priced compounded semaglutide and tirzepatide. AbundRX is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueBeyondMD +9
67
76
Dose & formulationEven
64
64
Clinical oversightAbundRX +5
79
74
Labs & monitoringEven
53
53
FulfillmentAbundRX +9
74
65
Contract termsEven
55
55
AbundRX · left barBeyondMD · right bar

The numbers

MetricAbundRXBeyondMD
WeighScore66.6/10066.8/100
GradeCC
Scorecard rank#181#176
Semaglutide$179/mo (compounded)$139/mo (starting dose, compounded)
Tirzepatide$279/mo (compounded)$209/mo (starting dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
AbundRX

Graded #181 · C

Strengths

  • Two clear compounded GLP-1 pathways with transparent pricing — semaglutide $179/mo and tirzepatide $279/mo
  • Fast, free shipping and a simple few-minute online health assessment
  • Provider-guided care connecting patients with licensed US clinicians
  • Publishes Terms, Privacy, and Refund policies

Where it loses points

  • Claims LegitScript certification in text but displays no verifiable seal or listing
  • Compounded medications are not FDA-approved (the site discloses this) — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • Compounding pharmacy not named; no HIPAA notice found; state availability not published
  • Heavily hedged marketing language ('may include', 'helping connect patients') — reads like a lead-generation platform
BeyondMD

Graded #176 · C

Strengths

  • Aggressively low monthly pricing
  • Both semaglutide and tirzepatide available
  • Compounded GLP-1 access

Where it loses points

  • Limited public information on program details

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard